These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 24771112)

  • 1. Cost-effectiveness of treatment strategies using combination disease-modifying anti-rheumatic drugs and glucocorticoids in early rheumatoid arthritis.
    Wailoo A; Hernández Alava M; Scott IC; Ibrahim F; Scott DL
    Rheumatology (Oxford); 2014 Oct; 53(10):1773-7. PubMed ID: 24771112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
    Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
    Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Uttley L; Bermejo I; Ren S; Martyn-St James M; Wong R; Scott DL; Young A; Stevenson M
    Pharmacoeconomics; 2018 Sep; 36(9):1063-1072. PubMed ID: 29546668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial.
    Hartman L; Rasch LA; Klausch T; Bijlsma HWJ; Christensen R; Smulders YM; Ralston SH; Buttgereit F; Cutolo M; Da Silva JAP; Opris D; Rovenský J; Szamosi S; Middelink LM; Lems WF; Boers M
    Trials; 2018 Jan; 19(1):67. PubMed ID: 29370811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis.
    Choy EH; Smith CM; Farewell V; Walker D; Hassell A; Chau L; Scott DL;
    Ann Rheum Dis; 2008 May; 67(5):656-63. PubMed ID: 17768173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
    Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
    Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Best cost-effectiveness and worker productivity with initial triple DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost-utility analysis of the tREACH trial.
    de Jong PH; Hazes JM; Buisman LR; Barendregt PJ; van Zeben D; van der Lubbe PA; Gerards AH; de Jager MH; de Sonnaville PB; Grillet BA; Luime JJ; Weel AE
    Rheumatology (Oxford); 2016 Dec; 55(12):2138-2147. PubMed ID: 27581208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of combination nonbiologic disease-modifying antirheumatic drug strategies in patients with early rheumatoid arthritis.
    Tosh JC; Wailoo AJ; Scott DL; Deighton CM
    J Rheumatol; 2011 Aug; 38(8):1593-600. PubMed ID: 21572149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial.
    Seegobin SD; Ma MH; Dahanayake C; Cope AP; Scott DL; Lewis CM; Scott IC
    Arthritis Res Ther; 2014 Jan; 16(1):R13. PubMed ID: 24433430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-year cost-effectiveness of different COBRA-like intensive remission induction schemes in early rheumatoid arthritis: a piggyback study on the pragmatic randomised controlled CareRA trial.
    Pazmino S; Boonen A; Stouten V; De Cock D; Joly J; Van der Elst K; Westhovens R; Verschueren P
    Ann Rheum Dis; 2020 May; 79(5):556-565. PubMed ID: 32241795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel etanercept biosimilar Anbainuo plus methotrexate exhibits increased cost-effectiveness compared to conventional disease-modifying anti-rheumatic drugs in treating rheumatoid arthritis patients.
    Tian F; Li JY; Wen ZH; Luo XW; Deng L; Zhang L; He JY
    Medicine (Baltimore); 2019 Nov; 98(48):e17750. PubMed ID: 31770193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of etanercept plus methotrexate vs triple therapy in treating Chinese rheumatoid arthritis patients.
    Shi ZC; Fei HP; Wang ZL
    Medicine (Baltimore); 2020 Jan; 99(3):e16635. PubMed ID: 32011430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany].
    Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
    Z Rheumatol; 2004 Feb; 63(1):59-75. PubMed ID: 14991279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Ren S; Bermejo I; Simpson E; Wong R; Scott DL; Young A; Stevenson M
    Pharmacoeconomics; 2018 Jul; 36(7):769-778. PubMed ID: 29502174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple Therapy Versus Biologic Therapy for Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis.
    Bansback N; Phibbs CS; Sun H; O'Dell JR; Brophy M; Keystone EC; Leatherman S; Mikuls TR; Anis AH;
    Ann Intern Med; 2017 Jul; 167(1):8-16. PubMed ID: 28554192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of low dose corticosteroids versus non-steroidal anti-inflammatory drugs and COX-2 specific inhibitors in the long-term treatment of rheumatoid arthritis.
    Bae SC; Corzillius M; Kuntz KM; Liang MH
    Rheumatology (Oxford); 2003 Jan; 42(1):46-53. PubMed ID: 12509612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective.
    Schipper LG; Kievit W; den Broeder AA; van der Laar MA; Adang EM; Fransen J; van Riel PL
    Rheumatology (Oxford); 2011 Jul; 50(7):1320-30. PubMed ID: 21371999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
    Brennan A; Bansback N; Nixon R; Madan J; Harrison M; Watson K; Symmons D
    Rheumatology (Oxford); 2007 Aug; 46(8):1345-54. PubMed ID: 17562686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect on Costs and Quality-adjusted Life-years of Treat-to-target Treatment Strategies Initiating Methotrexate, or Tocilizumab, or Their Combination in Early Rheumatoid Arthritis.
    Verhoeven MMA; Tekstra J; van Laar JM; Pethö-Schramm A; Borm MEA; Bijlsma JWJ; Jacobs JWG; Lafeber FPJG; Welsing PMJ
    J Rheumatol; 2021 Apr; 48(4):495-503. PubMed ID: 32739893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.